Abstract：
Primary cardiac lymphomas (PCLs) are a rare clinical entity, in which treatment guidelines remain to be established. Rituximab, etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (R-EPOCH) has been proposed, given that it involves a continuous infusion of anthracycline, reducing the risk of a cardiotoxicity and therefore the theoretical risk of perforation. However, the literature on this method of treatment is scarce. Herein, we present a unique case of a 75-year-old male, diagnosed with primary cardiac diffuse large B-cell lymphoma (DLBCL) with relatively unusual involvement of the coronary sinus, treated first with one cycle of R-EPOCH, followed by three cycles of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) to reduce said risk. To our knowledge, this is one of two cases, in which a patient with PCL was treated this way.
摘要：
原发性心脏淋巴瘤（PCL）是一种罕见的临床实体，其中治疗指南尚待制定。利妥昔单抗,依托泊苷,泼尼松,长春新碱,环磷酰胺,和阿霉素（R-EPOCH）已被提出，考虑到它涉及连续输注蒽环类抗生素，降低心脏毒性的风险，从而降低理论上的穿孔风险。然而,关于这种治疗方法的文献很少。在这里，我们展示了一个75岁男性的独特案例，诊断为原发性心脏弥漫性大B细胞淋巴瘤（DLBCL），冠状窦相对异常受累，首先用一个周期的R-EPOCH治疗，随后是利妥昔单抗的三个周期，环磷酰胺,阿霉素,长春新碱,和泼尼松（R-CHOP）以降低所述风险。据我们所知,这是两种情况之一，以这种方式治疗PCL患者。
